Evidence map›Paper›PMID 37714584›Full record

ReviewHeart failure clinics2023

Imaging in Hypertrophic Cardiomyopathy: Beyond Risk Stratification.

Zachariah Nealy, Christopher Kramer

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heart failure clinics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zachariah NealyCardiovascular Division, Department of Medicine, University of Virginia Health, Charlottesville, VA 22908, USA.
Christopher KramerCardiovascular Division, Department of Medicine, University of Virginia Health, Charlottesville, VA 22908, USA; Department of Radiology and Medical Imaging, University of Virginia Health, Charlottesville, VA 22908, USA. Electronic address: ckramer@virginia.edu.
University of Virginia · US

Funding

HCMR Novel Markers of Prognosis in Hypertrophic CardiomyopathyU01HL117006 · NHLBI · UNIVERSITY OF VIRGINIA · PI KRAMER, CHRISTOPHER M., NEUBAUER, STEFAN · 2013 to 2017
$14.5M
Training in Cardiovascular Imaging ResearchT32EB003841 · NIBIB · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jonathan R Lindner · 2004 to 2026
$4.4M
NHLBI NIH HHS U01 HL117006NIBIB NIH HHS T32 EB003841
6 · The paper itself

Abstract

A multimodality imaging evaluation in hypertrophic cardiomyopathy is often used for risk stratification. Recent developments in imaging have allowed for better diagnosis, prognosis, and decision-making for a variety of therapies from medical to interventional. Echocardiography and magnetic resonance have been integral in evaluating subtype, left ventricular function, tissue characterization, left atrial measurements, valvular function, and presence of left ventricular aneurysm and outflow tract obstruction. These factors have helped to quantify risk of atrial fibrillation and determine the likely usefulness of pharmacologic therapy and septal reduction therapy. This review covers these in detail.

Indexed as

Atrial FibrillationCardiomyopathy, HypertrophicEchocardiographyHumansMultimodal ImagingRisk AssessmentCMREchocardiographyHypertrophic cardiomyopathyImaging

Identifiers

PMID37714584
PMCPMC10800026
OpenAlexW4367396883

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.